HomeQuestion

What maintenance therapy, if any, do you offer patients with metastatic HER2+ esophageal or gastric cancer?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How do you differentiate between ERBB2 mutation vs HER2 overexpression testing when selecting patients for tumor-agnostic therapy?

Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?

How, if at all, will you incorporate durvalumab + FLOT in patients with HER2+ resectable gastric/GEJ adenocarcinoma?

What are your top takeaways from ASCO GI 2026?

How are you treating MSI-H CRC in a liver transplant recipient on tacrolimus & sirolimus?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.